Demir, Mehmet Emin

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14411/7115
Name Variants
Demir, M. E.
Mehmet Emin, Demir
Demir M.
Demir,M.E.
D.,Mehmet Emin
D., Mehmet Emin
M. E. Demir
M.E.Demir
Emin M.
Demir, Mehmet E.
M., Demir
Demir, Mehmet Emin
M.,Demir
Job Title
Doçent Doktor
Email Address
mehmet.demir@atilim.edu.tr
Main Affiliation
Internal Medical Sciences
Status
Website
ORCID ID
Scopus Author ID
57213282312
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
V-3453-2017

Sustainable Development Goals

2

ZERO HUNGER
ZERO HUNGER Logo

0

Research Products

14

LIFE BELOW WATER
LIFE BELOW WATER Logo

0

Research Products

17

PARTNERSHIPS FOR THE GOALS
PARTNERSHIPS FOR THE GOALS Logo

0

Research Products

5

GENDER EQUALITY
GENDER EQUALITY Logo

0

Research Products

16

PEACE, JUSTICE AND STRONG INSTITUTIONS
PEACE, JUSTICE AND STRONG INSTITUTIONS Logo

0

Research Products

8

DECENT WORK AND ECONOMIC GROWTH
DECENT WORK AND ECONOMIC GROWTH Logo

0

Research Products

4

QUALITY EDUCATION
QUALITY EDUCATION Logo

0

Research Products

6

CLEAN WATER AND SANITATION
CLEAN WATER AND SANITATION Logo

1

Research Products

7

AFFORDABLE AND CLEAN ENERGY
AFFORDABLE AND CLEAN ENERGY Logo

0

Research Products

10

REDUCED INEQUALITIES
REDUCED INEQUALITIES Logo

0

Research Products

11

SUSTAINABLE CITIES AND COMMUNITIES
SUSTAINABLE CITIES AND COMMUNITIES Logo

0

Research Products

9

INDUSTRY, INNOVATION AND INFRASTRUCTURE
INDUSTRY, INNOVATION AND INFRASTRUCTURE Logo

0

Research Products

1

NO POVERTY
NO POVERTY Logo

0

Research Products

3

GOOD HEALTH AND WELL-BEING
GOOD HEALTH AND WELL-BEING Logo

5

Research Products

12

RESPONSIBLE CONSUMPTION AND PRODUCTION
RESPONSIBLE CONSUMPTION AND PRODUCTION Logo

0

Research Products

13

CLIMATE ACTION
CLIMATE ACTION Logo

0

Research Products

15

LIFE ON LAND
LIFE ON LAND Logo

0

Research Products
Documents

30

Citations

361

h-index

8

Go to Scopus profile
Documents

47

Citations

500

Go to WoS profile
Scholarly Output

11

Articles

10

Views / Downloads

4/0

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

21

Scopus Citation Count

18

WoS h-index

2

Scopus h-index

2

Patents

0

Projects

0

WoS Citations per Publication

1.91

Scopus Citations per Publication

1.64

Open Access Source

10

Supervised Theses

0

Google Analytics Visitor Traffic

JournalCount
Frontiers in Immunology2
Frontiers in Public Health1
Frontiers in Systems Neuroscience1
International Journal of General Medicine1
International Urology and Nephrology1
Current Page: 1 / 2

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

20231
Reset filters

Settings

Author: Merhametsiz, OzgurSubject: Kidney transplantation

Scholarly Output Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Article
    Citation - WoS: 13
    Citation - Scopus: 15
    The Results of Sglt-2 Inhibitors Use in Kidney Transplantation: 1-Year Experiences From Two Centers
    (Springer, 2023) Demir, Mehmet Emin; Ozler, Tuba Elif; Merhametsiz, Ozgur; Sozener, Ulas; Uyar, Murathan; Ercan, Zafer; Turkmen Sariyildiz, Gulcin
    PurposeSodium-glucose co-transporter-2 inhibitor (SGLT-2i) administration is associated with some concerns in regard to the increased risk of genital and urinary tract infections (UTI) in kidney transplant recipients (KTR). In this study, we present the results of SGLT-2i use in KTR, including the early post-transplant period.MethodsParticipants were divided into two groups: SGLT-2i-free diabetic KTR (Group 1, n = 21) and diabetic KTR using SGLT-2i (Group 2, n = 36). Group 2 was further divided into two subgroups according to the posttransplant prescription day of SGLT-2i; < 3 months (Group 2a) and >= 3 months (Group 2b). Groups were compared for development of genital and urinary tract infections, glycated hemoglobin a1c (HgbA1c), estimated glomerular filtration rate (eGFR), proteinuria, weight change, and acute rejection rate during 12-month follow-up.ResultsUrinary tract infections prevalence was 21.1% and UTI-related hospitalization rate was 10.5% in our cohort. Prevalence of UTI and UTI-related hospitalization, eGFR, HgbA1c levels, and weight gain were similar between the SGLT-2i group and SGLT-2i-free group, at the 12-month follow-up. UTI prevalence was similar between groups 2a and 2b (p = 0.871). No case of genital infection was recorded. Significant proteinuria reduction was observed in Group 2 (p = 0.008). Acute rejection rate was higher in the SGLT-2i-free group (p = 0.040) and had an impact on 12-month follow-up eGFR (p = 0.003).ConclusionSGLT-2i in KTR is not associated with an increased risk of genital infection and UTI in diabetic KTR, even in the early posttransplant period. The use of SGLT-2i reduces proteinuria in KTR and has no adverse effects on allograft function at the 12-month follow-up.